Paul Cc Chew1, B Julaihi2, Za Ibrahim3. 1. Orthopaedic Clinic, Normah Medical Specialist Centre, Kuching, Malaysia. 2. Radiology Clinic, Normah Medical Specialist Centre, Kuching, Malaysia. 3. Department of Pathology, Universiti Malaysia Sarawak, Kuching, Malaysia.
Abstract
UNLABELLED: Spontaneous atypical fractures of the femur have been reported in patients on long-term antiresorptive bisphosphonate therapy. Here, we report a case of subtrochanteric stress fracture in a seventy-year-old female patient on long-term alendronate therapy, and accompanying management challenges. Potential measures to prevent this complication of antiresorptive treatment for osteoporosis include the following: setting strict criteria for prescribing antiresorptive therapy, limiting the duration of continuous antiresorptive therapy, and increasing the use of bone anabolic agents. KEY WORDS: atypical femoral fractures, alendronate, osteoporosis.
UNLABELLED: Spontaneous atypical fractures of the femur have been reported in patients on long-term antiresorptive bisphosphonate therapy. Here, we report a case of subtrochanteric stress fracture in a seventy-year-old female patient on long-term alendronate therapy, and accompanying management challenges. Potential measures to prevent this complication of antiresorptive treatment for osteoporosis include the following: setting strict criteria for prescribing antiresorptive therapy, limiting the duration of continuous antiresorptive therapy, and increasing the use of bone anabolic agents. KEY WORDS: atypical femoral fractures, alendronate, osteoporosis.
Recently, there has been an increase in the number of reports
describing atypical femoral diaphyseal and sub-trochanteric
fractures related to long-term usage of antiresorptive drugs
for the treatment of post-menopausal osteoporosis1,2.
Alendronate, a bisphosphonate, the most commonly used
antiresorptive drug was implicated in a few reports. Here, we
report a case of stress or insufficiency fracture in the subtrochanteric
region of the left femur in a female patient who
was prescribed alendronate for the previous six years,
highlighting the uncommon presentation and radiological
appearance of such fractures.
Case Report
A seventy-year-old female presented with two months'
history of left anterior thigh pain. She was not able to walk
for more than fifteen minutes because of the pain, but
reported no pain at rest and no history of trauma. Her
medical history included hypertension and
hypercholesterolemia for which atenolol and lovastatin were
prescribed. Physical examination showed scoliosis of the
lumbar spine, 'flat back', a positive Trendelenburg test and
ambulation with a marked limp. The patient had no
complaints of back pain on movement of the spine and the straight-leg-raising test was normal bilaterally. Hip and knee
movements were pain free. Differential clinical diagnosis
included referred pain from spinal pathology and pain arising
from the left hip or femur or thigh.Radiographs of the lumbosacral spine showed degenerative
scoliosis with spondylotic changes at multiple levels.
Radiographs of the pelvis showed very subtle thickening of
the lateral cortex in the sub-trochanteric region of the left
femur (Figure 1) and normal hip joints. Magnetic resonance
imaging (MRI) of the lumbosacral spine showed disc
degeneration at multiple levels with spinal canal stenosis at
L4/5 and L5/S1. MRI of the left femur revealed a
hypointense area in the subtrochanteric marrow in the T1
weighted image and hyperintensity on the T2 weighted
image. (Figure 2a, 2b); there was no further enhancement
with gadolinium. Differential diagnosis for such MRI
findings included stress fractures or osteomyelitis. Limited
computed tomography (CT) scan of this area confirmed a
linear fracture at the lateral cortex of the proximal femur.
(Figure 3a, 3b).
Fig. 1
: Radiograph of left hip showing a
subtle periosteal reaction (arrow)
in the subtrochanteric region of
the left femur.
Fig. 2a & 2b
: T1 weighted and T2 weighted magnetic resonance images of upper femur showing signal changes in the marrow at the level of the
periosteal reaction.
Fig. 3a & 3b
: Figure 3a and 3b are reconstructed images from a limited multislice CT scan of the left femur showing a thin oblique linear
fracture in the upper femur. There was no marrow lesion seen.
On further questioning, the patient revealed that she had
been taking alendronate for six years. Her general
practitioner prescribed alendronate treatment for chronic
backache. Dual energy X-ray absorptiometry (DEXA) scan
was not performed prior to or during treatment. A diagnosis
of alendronate-related stress fracture of the proximal left
femur was made.DEXA scan (Hologic Discovery) results were normal, with a
T-score of 0.6 for lumbar spine L1 to L4 and T-score of 1.0
for the right hip. Serum calcium, 25-hydroxy Vitamin D
level and intact parathyroid hormone levels were also
normal. Serum Beta-CrossLaps, a bone resorption marker
and an indicator of effectiveness of antiresorption therapy of
bisphosphonates, was normal at111ng/L. We do not have
pre-alendronate treatment results.Prophylactic intramedullary nailing was performed after
ascertaining that the patient’s femoral medullary canal could
accommodate a nail. The medullary canal was reamed to
thirteen millimeters to accommodate a ten millimeter nail.Insertion of the nail at the lower end of the femur was
difficult due to anterior bowing of the femur; this resulted in
conversion to a complete sub-trochanteric fracture. We then
implemented dynamic hip screw fixation to stabilize the
fracture (Figure 4a). Tightening of the screws further
extended the fracture. Curetted bone material from the defect
in the greater trochanteric region was sent for
histopathologic analysis (Figure 5).
Fig. 4a
: Radiograph showing dynamic hip screw fixation of the subtrochanteric fracture
Fig. 5
: Histology of bone from the left greater trochanter. (Haematoxylin and Eosin (H&E) staining, 40X magnification). Areas of
necrotic bone with empty lacunae indicated by black
Bisphosphonate therapy decreases the number or function of
osteoclasts by promoting apoptosis or inhibits osteoclast
action in bone remodeling, thereby inducing a progressive
increase in bone density. Stress fractures are caused by
micro-crack accumulation in bone that has not undergone
sufficient remodeling3. As expected, due to the
bisphosphonate therapy, we saw no osteoclasts in specimen
sent for analysis, indicating a lack of ongoing bone
remodeling. The sample (Figure 5) showed areas of necrotic bone with empty lacunae (black arrow) adjacent to viable
bone (blue arrow) and foci of micro-cracks seen at the
necrotic bone fragments (green arrow).Alendronate treatment was stopped and the patient was
started on recombinant parathyroid hormone (rPTH or
Forteo, Eli Lilly) therapy. Follow-up x-rays showed union of
the fracture (Figure 4b), and by that time the patient could
walk without pain.
Fig. 4b
: Radiograph taken two months postoperatively showing healing callus formation
Discussion
Bisphosphonates have been shown to reduce rates of spinal
and extra-spinal fragility fractures in patients with prior
osteoporotic fractures. However, concerns exist about the
effects of long-term suppression of bone resorption and
remodeling on bone strength. Although this is reflected in
many reports of atypical femur fractures in patients on longterm
bisphosphonate therapy, large population studies have
not shown conclusive evidence of direct causation4,5. The
number of reported fractures is too small and the variance
too wide to allow authors to draw definitive conclusions.The following reported figures are cause for concern. In a
review of 12,777 women aged 55 years or older with
fractures of the femur in Sweden in 2008, 59 patients with
atypical femoral fractures were identified. Of the 59
fractures, 46 were long-term bisphosphonate users (crude
incidence of 5.5 fractures per 10,000 patient-year) 5. Of
additional concern, bisphosphonates are now more widely
used due to the availability of cheaper generic equivalents,
and increasingly affluent society and increased public
awareness of the importance of osteoporosis treatment.The present case involved an uncommon presentation of a
stress fracture with minimal changes in plain radiography.
CT Scan was more useful to detect breaks in cortical
continuity, while MRI clearly showed intra-medullary and
periosteal bone changes. Further, this case illustrates the fact
that osteoporosis treatment must be instituted appropriately
and monitored for possible complications. Alternative
strategies such as intermittent bisphosphonate therapy or
drug ‘holidays’ should be considered. Alternating
antiresorptive treatment with a bone anabolic agent like
rPTH is also an attractive alternative, but the high cost of
rPTH and the need for daily subcutaneous injections limit
widespread adoption of this strategy. In stress fractures,
decisions regarding the mode of internal fixation can be
challenging.: Radiograph of left hip showing a
subtle periosteal reaction (arrow)
in the subtrochanteric region of
the left femur.: T1 weighted and T2 weighted magnetic resonance images of upper femur showing signal changes in the marrow at the level of the
periosteal reaction.: Figure 3a and 3b are reconstructed images from a limited multislice CT scan of the left femur showing a thin oblique linear
fracture in the upper femur. There was no marrow lesion seen.: Radiograph showing dynamic hip screw fixation of the subtrochanteric fracture: Radiograph taken two months postoperatively showing healing callus formation: Histology of bone from the left greater trochanter. (Haematoxylin and Eosin (H&E) staining, 40X magnification). Areas of
necrotic bone with empty lacunae indicated by black
Authors: Dennis M Black; Michael P Kelly; Harry K Genant; Lisa Palermo; Richard Eastell; Christina Bucci-Rechtweg; Jane Cauley; Ping Chung Leung; Steven Boonen; Arthur Santora; Anne de Papp; Douglas C Bauer Journal: N Engl J Med Date: 2010-03-24 Impact factor: 91.245
Authors: Denise M van de Laarschot; Malachi J McKenna; Bo Abrahamsen; Bente Langdahl; Martine Cohen-Solal; Núria Guañabens; Richard Eastell; Stuart H Ralston; M Carola Zillikens Journal: J Clin Endocrinol Metab Date: 2020-05-01 Impact factor: 5.958